Pyrimidine derivatives useful as inhibitors of PKC-theta
US7601714B2 · kind B2 · utility
31Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2005 |
| Grant date | Oct 13, 2009 |
| Priority date | — |
| Expiry date | Jan 21, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel compounds of formula (I):wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.